Literature DB >> 32347983

Mitochondrial Complex 1, Sigma 1, and Synaptic Vesicle 2A in Early Drug-Naive Parkinson's Disease.

Heather Wilson1,2, Gennaro Pagano2, Edoardo Rosario de Natale1,2, Ayla Mansur3,4, Silvia Paola Caminiti2, Sotirios Polychronis2, Lefkos T Middleton5,6,7, Geraint Price5,7, Karl F Schmidt8, Roger N Gunn3,4,7, Eugenii A Rabiner3,7,9, Marios Politis1,2,7.   

Abstract

BACKGROUND: Dysfunction of mitochondrial energy generation may contribute to neurodegeneration, leading to synaptic loss in Parkinson's disease (PD). The objective of this study was to find cross-sectional and longitudinal changes in PET markers of synaptic vesicle protein 2A, sigma 1 receptor, and mitochondrial complex 1 in drug-naive PD patients.
METHODS: Twelve early drug-naive PD patients and 16 healthy controls underwent a 3-Tesla MRI and PET imaging to quantify volume of distribution of [11 C]UCB-J, [11 C]SA-4503, and [18 F]BCPP-EF for synaptic vesicle protein 2A, sigma 1 receptor, and mitochondrial complex 1, respectively. Nine PD patients completed approximately 1-year follow-up assessments.
RESULTS: Reduced [11 C]UCB-J volume of distribution in the caudate, putamen, thalamus, brain stem, and dorsal raphe and across cortical regions was observed in drug-naive PD patients compared with healthy controls. [11 C]UCB-J volume of distribution was reduced in the locus coeruleus and substantia nigra but did not reach statistical significance. No significant differences were found in [11 C]SA-4503 and [18 F]BCPP-EF volume of distribution in PD compared with healthy controls. Lower brain stem [11 C]UCB-J volume of distribution correlated with Movement Disorder Society Unified Parkinson's Disease Rating Scale part III and total scores. No significant longitudinal changes were identified in PD patients at follow-up compared with baseline.
CONCLUSIONS: Our findings represent the first in vivo evidence of mitochondrial, endoplasmic reticulum, and synaptic dysfunction in drug-naive PD patients. Synaptic dysfunction likely occurs early in disease pathophysiology and has relevance to symptomatology. Mitochondrial complex 1 and sigma 1 receptor pathology warrants further investigations in PD. Studies in larger cohorts with longer follow-up will determine the validity of these PET markers to track disease progression.
© 2020 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society. © 2020 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Parkinson's disease; mitochondria; molecular biomarkers; positron emission tomography; synaptic vesicle protein

Mesh:

Substances:

Year:  2020        PMID: 32347983     DOI: 10.1002/mds.28064

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  10 in total

1.  NRM 2021 Abstract Booklet.

Authors: 
Journal:  J Cereb Blood Flow Metab       Date:  2021-12       Impact factor: 6.960

Review 2.  Synaptic Vesicle Glycoprotein 2A: Features and Functions.

Authors:  Rachele Rossi; Shokouh Arjmand; Simone Larsen Bærentzen; Albert Gjedde; Anne M Landau
Journal:  Front Neurosci       Date:  2022-04-28       Impact factor: 5.152

3.  Mitochondrial Respiratory Chain Dysfunction-A Hallmark Pathology of Idiopathic Parkinson's Disease?

Authors:  Irene H Flønes; Charalampos Tzoulis
Journal:  Front Cell Dev Biol       Date:  2022-04-01

Review 4.  Targeting mitophagy in Parkinson's disease.

Authors:  Emily H Clark; Aurelio Vázquez de la Torre; Tamaki Hoshikawa; Thomas Briston
Journal:  J Biol Chem       Date:  2020-12-24       Impact factor: 5.157

Review 5.  Novel PET Biomarkers to Disentangle Molecular Pathways across Age-Related Neurodegenerative Diseases.

Authors:  Heather Wilson; Marios Politis; Eugenii A Rabiner; Lefkos T Middleton
Journal:  Cells       Date:  2020-12-02       Impact factor: 6.600

Review 6.  Genotype-driven therapeutic developments in Parkinson's disease.

Authors:  Jannik Prasuhn; Norbert Brüggemann
Journal:  Mol Med       Date:  2021-04-19       Impact factor: 6.354

Review 7.  Monogenetic Forms of Parkinson's Disease - Bridging the Gap Between Genetics and Biomarkers.

Authors:  Lars Tönges; Eun Hae Kwon; Stephan Klebe
Journal:  Front Aging Neurosci       Date:  2022-03-03       Impact factor: 5.750

8.  Automated Synthesis of 18F-BCPP-EF {2-tert-Butyl-4-Chloro-5-{6-[2-(2[18F]fluoroethoxy)-Ethoxy]-Pyridin-3-ylmethoxy}-2H-Pyridazin-3-One for Imaging of Mitochondrial Complex 1 in Parkinson's Disease.

Authors:  Tanpreet Kaur; Allen F Brooks; Katherine M Liddell; Bradford D Henderson; Brian G Hockley; Nicolaas I Bohnen; Roger L Albin; Peter J H Scott
Journal:  Front Chem       Date:  2022-03-30       Impact factor: 5.221

Review 9.  Neuroimaging Methods to Map In Vivo Changes of OXPHOS and Oxidative Stress in Neurodegenerative Disorders.

Authors:  Jannik Prasuhn; Liesa Kunert; Norbert Brüggemann
Journal:  Int J Mol Sci       Date:  2022-06-30       Impact factor: 6.208

10.  α-Synuclein Overexpression Increases Dopamine D2/3 Receptor Binding and Immune Activation in a Model of Early Parkinson's Disease.

Authors:  Kathrine Stokholm; Majken Borup Thomsen; Jenny-Ann Phan; Line K Møller; Cecilie Bay-Richter; Søren H Christiansen; David P D Woldbye; Marina Romero-Ramos; Anne M Landau
Journal:  Biomedicines       Date:  2021-12-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.